126 related articles for article (PubMed ID: 21703849)
21. An elevated serum beta-2-microglobulin level is an adverse prognostic factor for overall survival in patients with early-stage Hodgkin disease.
Chronowski GM; Wilder RB; Tucker SL; Ha CS; Sarris AH; Hagemeister FB; Barista I; Hess MA; Cabanillas F; Cox JD
Cancer; 2002 Dec; 95(12):2534-8. PubMed ID: 12467067
[TBL] [Abstract][Full Text] [Related]
22. Salvage radiotherapy in patients with relapsed and refractory Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group.
Josting A; Nogová L; Franklin J; Glossmann JP; Eich HT; Sieber M; Schober T; Boettcher HD; Schulz U; Müller RP; Diehl V; Engert A
J Clin Oncol; 2005 Mar; 23(7):1522-9. PubMed ID: 15632410
[TBL] [Abstract][Full Text] [Related]
23. Advanced Hodgkin disease with large mediastinal involvement can be treated with eight cycles of chemotherapy alone after a major response to six cycles of chemotherapy: a study of 82 patients from the Groupes d'Etudes des Lymphomes de l'Adulte H89 trial.
Brice P; Colin P; Berger F; de Kerviler E; Diviné M; Bouaffia F; Kerneis Y; Blanc M; Lepage E; Fermé C;
Cancer; 2001 Aug; 92(3):453-9. PubMed ID: 11505388
[TBL] [Abstract][Full Text] [Related]
24. Reduced intensity VEPEMB regimen compared with standard ABVD in elderly Hodgkin lymphoma patients: results from a randomized trial on behalf of the Fondazione Italiana Linfomi (FIL).
Zallio F; Tamiazzo S; Monagheddu C; Merli F; Ilariucci F; Stelitano C; Liberati AM; Mannina D; Vitolo U; Angelucci E; Rota Scalabrini D; Vallisa D; Bellei M; Bari A; Ciccone G; Salvi F; Levis A
Br J Haematol; 2016 Mar; 172(6):879-88. PubMed ID: 26763986
[TBL] [Abstract][Full Text] [Related]
25. Combined modality therapy in previously untreated patients with advanced Hodgkin's disease: A 24-year follow-up study.
Salloum E; Doria R; Farber LR; Roberts KB; Cooper DL
Cancer J Sci Am; 1995; 1(4):267-73. PubMed ID: 9166487
[TBL] [Abstract][Full Text] [Related]
26. Hodgkin lymphoma: MOPP chemotherapy to PD-1 blockade and beyond.
Ansell SM
Am J Hematol; 2016 Jan; 91(1):109-12. PubMed ID: 26505486
[TBL] [Abstract][Full Text] [Related]
27. [Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma].
Fu XH; Wang SS; Huang Y; Wang B; Huang HQ; Zhang L; Sun XF; Xu RH; Lin TY
Ai Zheng; 2006 Aug; 25(8):1013-8. PubMed ID: 16965685
[TBL] [Abstract][Full Text] [Related]
28. Chemotherapy and irradiation in childhood Hodgkin's disease.
Robinson B; Kingston J; Nogueira Costa R; Malpas JS; Barrett A; McElwain TJ
Arch Dis Child; 1984 Dec; 59(12):1162-7. PubMed ID: 6546191
[TBL] [Abstract][Full Text] [Related]
29. [Clinical analysis of childhood and adolescent Hodgkin's lymphoma: a report of 88 cases].
Xing PY; Shi YK; He XH; Zhou LQ; Dong M; Yang JL; Liu P
Zhonghua Zhong Liu Za Zhi; 2012 Sep; 34(9):692-7. PubMed ID: 23159084
[TBL] [Abstract][Full Text] [Related]
30. Outcome of pediatric advanced Hodgkin lymphoma treated with ABVD and predictors of inferior survival: a multicenter study of 186 patients.
Bhethanabhotla S; Jain S; Kapoor G; Mahajan A; Chopra A; Vishnubhatla S; Bakhshi S
Leuk Lymphoma; 2017 Jul; 58(7):1617-1623. PubMed ID: 27919174
[TBL] [Abstract][Full Text] [Related]
31. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial.
Engert A; Franklin J; Eich HT; Brillant C; Sehlen S; Cartoni C; Herrmann R; Pfreundschuh M; Sieber M; Tesch H; Franke A; Koch P; de Wit M; Paulus U; Hasenclever D; Loeffler M; Müller RP; Müller-Hermelink HK; Dühmke E; Diehl V
J Clin Oncol; 2007 Aug; 25(23):3495-502. PubMed ID: 17606976
[TBL] [Abstract][Full Text] [Related]
32. [Primary refractory and relapsed Hodgkin lymphoma with unfavorable prognosis].
Tarasenkova AA; Filatova LV; Gershanovich ML; Semiglazova TIu
Vopr Onkol; 2012; 58(1):101-9. PubMed ID: 22629838
[TBL] [Abstract][Full Text] [Related]
33. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E
Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727
[TBL] [Abstract][Full Text] [Related]
34. Long-term events in adult patients with clinical stage IA-IIA nonbulky Hodgkin's lymphoma treated with four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine and adjuvant radiotherapy: a single-institution 15-year follow-up.
Brusamolino E; Baio A; Orlandi E; Arcaini L; Passamonti F; Griva V; Casagrande W; Pascutto C; Franchini P; Lazzarino M
Clin Cancer Res; 2006 Nov; 12(21):6487-93. PubMed ID: 17085663
[TBL] [Abstract][Full Text] [Related]
35. Outcome of patients older than 60 years with classical Hodgkin lymphoma treated with front line ABVD chemotherapy: frequent pulmonary events suggest limiting the use of bleomycin in the elderly.
Stamatoullas A; Brice P; Bouabdallah R; Mareschal S; Camus V; Rahal I; Franchi P; Lanic H; Tilly H
Br J Haematol; 2015 Jul; 170(2):179-84. PubMed ID: 25891777
[TBL] [Abstract][Full Text] [Related]
36. Early versus late intensification for patients with high-risk Hodgkin lymphoma-3 cycles of intensive chemotherapy plus low-dose lymph node radiation therapy versus 4 cycles of combined doxorubicin, bleomycin, vinblastine, and dacarbazine plus myeloablative chemotherapy with autologous stem cell transplantation: five-year results of a randomized trial on behalf of the GOELAMS Group.
Arakelyan N; Berthou C; Desablens B; de Guibert S; Delwail V; Moles MP; Quittet P; Jais JP; Colonna P; Andrieu JM;
Cancer; 2008 Dec; 113(12):3323-30. PubMed ID: 18988286
[TBL] [Abstract][Full Text] [Related]
37. Long-term follow-up of survival in Hodgkin's lymphoma.
Canellos GP; Niedzwiecki D; Johnson JL
N Engl J Med; 2009 Dec; 361(24):2390-1. PubMed ID: 20007568
[No Abstract] [Full Text] [Related]
38. Long-term outcome in children with Hodgkin's lymphoma: the United Kingdom Children's Cancer Study Group HD82 trial.
Capra M; Hewitt M; Radford M; Hayward J; Weston CL; Machin D;
Eur J Cancer; 2007 May; 43(7):1171-9. PubMed ID: 17379506
[TBL] [Abstract][Full Text] [Related]
39. ChlVPP/EVA hybrid versus the weekly VAPEC-B regimen for previously untreated Hodgkin's disease.
Radford JA; Rohatiner AZ; Ryder WD; Deakin DP; Barbui T; Lucie NP; Rossi A; Dunlop DJ; Cowan RA; Wilkinson PM; Gupta RK; James RD; Shamash J; Chang J; Crowther D; Lister TA
J Clin Oncol; 2002 Jul; 20(13):2988-94. PubMed ID: 12089229
[TBL] [Abstract][Full Text] [Related]
40. Will BEACOPP be the standard for high risk Hodgkin lymphoma patients in advanced stages?
Diehl V; Fuchs M;
Transfus Apher Sci; 2007 Aug; 37(1):37-41. PubMed ID: 17714996
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
